Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neuro…
$16.66+0.06%
报价 2026-11-13
市值
$3.04B
EV
$2.87B
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 0.0%
$5.29$16.66
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-13不在筛选范围：industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| XERSXeris Biopharma Holdings, Inc. | $3.04B | +0.1% | +39.3% | 84.4% | – | 109.0x | 38.2x | |
| ABCLAbCellera Biologics Inc. | $3.75B | -1.1% | – | 75% | – | – | – | |
| CLDXCelldex Therapeutics, Inc. | $2.26B | +1.1% | -51.9% | 100% | – | – | – | |
| BHVNBiohaven Ltd. | $2.09B | -1.8% | +55466.7% | 0% | – | – | – | |
| VERAVera Therapeutics, Inc. | $2.03B | -3.2% | +201.6% | 0% | – | – | – | |
| HRMYHarmony Biosciences Holdings, Inc. | $1.98B | -0.1% | +18.9% | 77.2% | 10.0x | 4.3x | 6.1x | |
| BCRXBioCryst Pharmaceuticals, Inc. | $1.96B | -0.9% | +16.0% | 97.7% | 7.8x | 7.0x | 5.6x | |
| MAZEMaze Therapeutics, Inc. | $1.88B | -4.9% | +545.2% | 95.3% | – | – | – | |
| IMCRImmunocore Holdings plc | $1.55B | -1.8% | – | 98.7% | – | – | – | |
| 同行中位数 | – | – | +110.2% | 86.2% | 8.9x | 5.6x | 5.9x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。